Patents by Inventor Ian Lewis
Ian Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140249139Abstract: The invention relates to substituted quinazoline derivative of the formula (I), wherein A, X1, X2, X3, X4 and R5 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: October 19, 2012Publication date: September 4, 2014Applicant: NOVARTIS AGInventors: Pascal Furet, Christina Hebach, Klemens Hogenauer, Gregory Hollingworth, Ian Lewis, Alexander Baxter Smith, Nicolas Solvermann, Frederic Stauffer, Romain Wolf, Frederic Zecri
-
Patent number: 8822637Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O-)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: March 16, 2011Date of Patent: September 2, 2014Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Patent number: 8619086Abstract: Three dimensional scenes may be managed between a central processing unit and a graphics processing unit using shared and unified graphics processing unit memory. A shared bus memory may be synchronized between the central processing unit and the graphics processing unit. The shared bus memory may be used for more often updated components and other memory may be used for less often updated components. In some embodiments, if the graphics processor and the central processor use a common processor instruction set architecture, data can be sent from the central processor to the graphics processor without serializing the data.Type: GrantFiled: April 30, 2009Date of Patent: December 31, 2013Assignee: Intel CorporationInventors: Antony Arciuolo, Ian Lewis, Kevin Myers
-
Publication number: 20110172157Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: ApplicationFiled: March 16, 2011Publication date: July 14, 2011Applicant: NOVARTIS AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20110166320Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: ApplicationFiled: March 16, 2011Publication date: July 7, 2011Applicant: NOVARTIS AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Patent number: 7939625Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: November 5, 2008Date of Patent: May 10, 2011Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20110052538Abstract: This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH, increased carbohydrate fermentation, and amelioration of protein fermentation.Type: ApplicationFiled: October 18, 2010Publication date: March 3, 2011Applicant: BRUNOB II B.V.Inventors: Ian Lewis Brown, Anne M. Birkett, Richard Le Leu, Graeme P. Young
-
Patent number: 7847547Abstract: A method of determining a concentration level of a compound in a mixture is provided. A plurality of compounds are identified in the mixture based on intensity peaks identified from NMR data generated from the mixture. A compound is selected from the identified plurality of compounds for a concentration determination. A concentration equation associated with the selected compound is determined. A first peak associated with the selected compound is selected from the NMR data. The selected first peak does not overlap with a peak associated with another compound of the identified plurality of compounds. An intensity value associated with the selected first peak is determined. A concentration of the selected compound in the mixture is calculated using the determined concentration equation and the determined intensity value.Type: GrantFiled: January 30, 2008Date of Patent: December 7, 2010Assignee: Wisconsin Alumni Research FoundationInventors: John L. Markley, Ian A. Lewis, William M. Westler, Qiu Cui, Gabriel Cornilescu, Marco Tonelli
-
Publication number: 20100277488Abstract: A rasterizer may use only triangle position information. In this way, it is not necessary to rasterize objects that end up being culled in screen space.Type: ApplicationFiled: April 30, 2009Publication date: November 4, 2010Inventors: Kevin Myers, Antony Arciuolo, Ian Lewis
-
Publication number: 20100277484Abstract: Three dimensional scenes may be managed between a central processing unit and a graphics processing unit using shared and unified graphics processing unit memory. A shared bus memory may be synchronized between the central processing unit and the graphics processing unit. The shared bus memory may be used for more often updated components and other memory may be used for less often updated components. In some embodiments, if the graphics processor and the central processor use a common processor instruction set architecture, data can be sent from the central processor to the graphics processor without serializing the data.Type: ApplicationFiled: April 30, 2009Publication date: November 4, 2010Inventors: Antony Arciuolo, Ian Lewis, Kevin Myers
-
Publication number: 20100087491Abstract: The invention relates to novel diaryl oxadiazole compounds of Formula I: in which all the variables are as defined in the specification; to their preparation and to their use in the treatment of disorder or disease mediated by lymphocytes.Type: ApplicationFiled: September 27, 2007Publication date: April 8, 2010Inventors: Rainer Albert, Nigel Graham Cooke, Ian Lewis, Sven Weiler, Frederic Zecri
-
Patent number: 7666877Abstract: Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or -phenyl-C1-4alkyl; optionally R10 and/or R11-substituted-heteroaryl or -heteroaryl-C1-4alkyl; optionally R10 and/or R11-substituted heteroaryl N-oxide; optionally R10-substituted C1-C8 alkyl; optionally R10-substituted C2-C8 alkenyl, optionally R10-substituted C2-C8 alkynyl; optionally R10-substituted C3-C8 cycloalkyl, or optionally R10-substituted C4-C8 cycloalkenyl; or R1 and R2 form together with the nitrogen atom to which they are attached an optionally R10-substituted 3-8 membered ring containing in addition to the nitrogen atom up to 2 heteroatoms selected independently from N, O and S; R3 is H; OR1; CH2R1R2; (CH2)1-2NR1R2; CH2—CH2—OR1; CH2—CO—NR1R2; or CO—CH2R1R2; R4 is F; Cl; Br; I; OR1; NR1R2 or has one of the significances given for R1; and R5 has one of the significances given for R1, in free form or in salt form for preventing or treating disordersType: GrantFiled: May 29, 2006Date of Patent: February 23, 2010Assignee: Novartis AGInventors: Rolf Baenteli, Fraser Glickman, Jiri Kovarik, Ian Lewis, Markus Streiff, Gebhard Thoma, Hans-Günter Zerwes
-
Publication number: 20090192725Abstract: A method of determining a concentration level of a compound in a mixture is provided. A plurality of compounds are identified in the mixture based on intensity peaks identified from NMR data generated from the mixture. A compound is selected from the identified plurality of compounds for a concentration determination. A concentration equation associated with the selected compound is determined. A first peak associated with the selected compound is selected from the NMR data. The selected first peak does not overlap with a peak associated with another compound of the identified plurality of compounds. An intensity value associated with the selected first peak is determined. A concentration of the selected compound in the mixture is calculated using the determined concentration equation and the determined intensity value.Type: ApplicationFiled: January 30, 2008Publication date: July 30, 2009Inventors: John L. Markley, Ian A. Lewis, William M. Westler, Qiu Cui, Gabriel Cornilescu, Marco Tonelli
-
Publication number: 20090069225Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: ApplicationFiled: November 5, 2008Publication date: March 12, 2009Applicant: NOVARTIS AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20090018127Abstract: Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or -phenyl-C1-4alkyl; optionally R10 and/or R11-substituted-heteroaryl or -heteroaryl-C1-4alkyl; optionally R10 and/or R11-substituted heteroaryl N-oxide; optionally R10-substituted C1-C8 alkyl; optionally R10-substituted C2-C8 alkenyl, optionally R10-substituted C2-C8 alkynyl; optionally R10-substituted C3-C8 cycloalkyl, or optionally R10-substituted C4-C8 cycloalkenyl; or R1 and R2 form together with the nitrogen atom to which they are attached an optionally R10-substituted 3-8 membered ring containing in addition to the nitrogen atom up to 2 heteroatoms selected independently from N, O and S; R3 is H; OR1; CH2R1R2; (CH2)1-2NR1R2; CH2—CH2—OR1; CH2—CO—NR1R2; or CO—CH2R1R2; R4 is F; Cl; Br; I; OR1; NR1R2 or has one of the significances given for R1; and R5 has one of the significances given for R1, in free form or in salt form for preventing or treating disordersType: ApplicationFiled: May 29, 2006Publication date: January 15, 2009Inventors: Rolf Baenteli, Fraser Glickman, Jiri Kovarik, Ian Lewis, Markus Streiff, Gebhard Thoma, Hans-Gunter Zerwes
-
Patent number: 7473761Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: July 30, 2001Date of Patent: January 6, 2009Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20080318838Abstract: PTH compounds having PTH-like activity and comprising at least one modification, said modification being either 1. at least one radical selected from a L- or D-?-amino acid, C2-6alcoxycarbonyl and optionally substituted C1-8alkyl, C2-8alkenyl, C2-8alkynyl, aralkyl, aralkenyl or C3-6cycloalkyl-C1-4alkyl and attached to the terminal amino group of the PTH compound, and/or at least one radical selected from C2-6alcoxycarbonyl and optionally substituted C1-8alkyl, C2-8alkenyl, C2-8alkynyl, aralkyl, aralkenyl or C3-6cycloalkyl-C1-4alkyl and attached to one or more side chain amino groups of the PTH compound, or 2.Type: ApplicationFiled: July 8, 2008Publication date: December 25, 2008Inventors: Wilfried Bauer, Robin Breckenridge, Francois Cardinaux, Frank Gombert, Hermann Gram, Paul Ramage, Helmut Schneider, Rudolf Waelchli, Rainer Albert, Ian Lewis
-
Publication number: 20080292773Abstract: The present invention relates to the use of a modified starch to increase the dietary fiber content of food compositions processed under harsh conditions. By using certain modified starches, food formulations may be harshly processed while retaining substantial dietary fiber. Further, such modified starches provide dietary fiber without the negative effects on textural or organoleptic properties of the food compositions which are typically associated with the addition of other dietary fiber sources.Type: ApplicationFiled: May 9, 2007Publication date: November 27, 2008Inventors: Ian Lewis Brown, Monika Okoniewska, Robert L. Billmers
-
Publication number: 20080092249Abstract: The present invention relates to nuclear methods and embryos developed therefrom. In particular, the present invention relates to a method of nuclear comprising the step of transferring a somatic cell nuclei into a zona pellucida-free, enucleated oocyte.Type: ApplicationFiled: June 8, 2007Publication date: April 17, 2008Applicant: MONASH UNIVERSITYInventors: Ian Lewis, Gabor Vajta, Tayfur Tecirlioglu
-
Publication number: 20080069861Abstract: This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH, increased carbohydrate fermentation, and amelioration of protein fermentation.Type: ApplicationFiled: July 5, 2007Publication date: March 20, 2008Applicant: National Starch and Chemical Investment Holding CorporationInventors: Ian Lewis Brown, Anne M. Birkett, Richard Le Leu, Graeme P. Young
-
Patent number: 5260280Abstract: Sialic acid binding proteins, sialic acid-binding peptides and sialic acid containing oligo-saccharides are active ingredients of a novel bacterial enterotoxin neutralizer and interfere with the binding of enterotoxins, including cholera toxin, to receptors so as to exert an effect of neutralizing the toxicity, thus being utilized as an effective neutralizer and are safe and available cheaply and abundantly from by-products produced during the processing of cow's milk which renders the enterotoxin neutralizer economically advantageous for commercial use.Type: GrantFiled: July 14, 1992Date of Patent: November 9, 1993Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Hiroko Isoda, Yoshihiro Kawasaki, Morimasa Tanimoto, Shunichi Dosako, Tadashi Idota